GBT Announces New Employment Inducement Grants
September 04 2020 - 08:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that on September 1, 2020, the compensation
committee of GBT’s board of directors granted seven new employees
options to purchase an aggregate of 11,678 shares of the company’s
common stock with a per share exercise price of $60.45 and
restricted stock units for an aggregate of 46,585 shares of the
company’s common stock. These awards were made under GBT’s Amended
and Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by GBT’s
board of directors in January 2017 and has been amended and
restated from time to time.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical
company dedicated to the discovery, development, and delivery of
life-changing treatments that provide hope to underserved patient
communities. Founded in 2011, GBT is delivering on its goal to
transform the treatment and care of sickle cell disease (SCD), a
lifelong, devastating inherited blood disorder. The company has
introduced Oxbryta® (voxelotor), the first FDA-approved
treatment that directly inhibits sickle hemoglobin polymerization,
the root cause of red blood cell sickling in SCD. GBT is also
advancing its pipeline program in SCD with inclacumab, a p-selectin
inhibitor in development to address pain crises associated with the
disease. In addition, GBT’s drug discovery teams are working on new
targets to develop the next generation of treatments for SCD. To
learn more, please visit www.gbt.com and follow the
company on Twitter @GBT_news.
Contact Information:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors)650-741-7730syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2023 to Mar 2024